[Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
The Authors, after emphasizing melanoma still now represents one of the most aggressive malignant tumours, state the chemoimmunotherapeutic protocol they used in the treatment of this neoplasm. Then, on the basis of the results obtained, they affirm that, although malignant melanoma is considered from long time as a scarcely chemosensitive neoplasm, remarkable advantages can be got through the use of monochemotherapy, especially in association pith the immunotherapy. In fact, by associating both protocols, chemotherapeutic and immunotherapeutic a significant improvement in the prognosis of such neoplasm was obtained, as to both the indices of survival and the gap free from illness.
D001500:BCG Vaccine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine; D003606:Dacarbazine
Risultati dell'impiego dell'immunochemioterapia in pazienti con melanoma maligno cutaneo.